Authorities: Those under 30 who received 1st dose of AZ vaccine will get AZ vaccine for 2nd dose as well
Pfizer Vaccine Cross-Vaccination Possibility Ruled Out
![[Image source=Yonhap News]](http://www.asiae.co.kr/news/img_view.htm?img=2021041815554185719_1618728942.jpg)
[Asia Economy Reporter Kim Ji-hee] The government has reaffirmed its stance to administer the same AstraZeneca (AZ) COVID-19 vaccine for the second dose to recipients under 30 years old who have already received the first dose of the AZ vaccine. Previously, the AZ vaccine was excluded from the vaccination target for those under 30 due to rare blood clot controversies, but if the first dose was already administered without any adverse effects, the second dose will also be given.
On the 12th, Hong Jeong-ik, head of the COVID-19 Vaccination Response Promotion Team’s Vaccination Planning Team, said at a briefing, "South Korea has not yet decided on heterologous vaccination," adding, "We need to review the scientific evidence." He explained, "It is predicted that many young people under 30 experienced systemic adverse reactions during the first dose of the AZ vaccine," but "the frequency of adverse reactions decreases with the second dose."
Hong also stated, "Even if you had severe chills and fever during the first dose, the frequency significantly decreases with the second dose," and "there are no restrictions on vaccination for those who did not experience adverse reactions during the first dose." This means that heterologous vaccination, where those under 30 who received the AZ vaccine for the first dose receive the Pfizer vaccine for the second dose, is not allowed.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Japan's Q1 GDP Grows 0.5%, Annualized Rate Up 2.1%
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Regarding the judgment that the second dose will also be safe if there were no severe adverse reactions during the first dose, he explained, "The safety of vaccines is proven through clinical trials and then approved," adding, "If the reaction is caused by the vaccine, it is theoretically highly likely that if no problems appeared during the first dose, none will appear during the second dose."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
